GlaxoSmithKline announced plans to launch five new vaccines over the next five years. All told, the new drugs have a projected market value of $11 billion to $18 billion. The five include Cervarix, designed to protect against cervical cancer; Rotarix, which fights rotavirus gastroenteritis; and Streptorix, for pneumococcal disease. The company is also touting an improved flu vaccine and a new combination designed to combat meningitis.
- see this story from the Philadelphia Business Journal